Eaton Vance Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $4.34M | Sell |
37,142
-389
| -1% | -$48.3K | 0.01% | 825 |
|
|
2022
Q2 | $4.42M | Sell |
37,531
-2,196
| -6% | -$261K | 0.01% | 843 |
|
|
2022
Q1 | $5.18M | Buy |
39,727
+8,737
| +28% | +$1.14M | 0.01% | 877 |
|
|
2021
Q4 | $4.73M | Buy |
30,990
+1,110
| +4% | +$172K | 0.01% | 799 |
|
|
2021
Q3 | $4.78M | Sell |
29,880
-2,010
| -6% | -$338K | 0.01% | 733 |
|
|
2021
Q2 | $5.22M | Sell |
31,890
-808
| -2% | -$124K | 0.01% | 775 |
|
|
2021
Q1 | $4.92M | Buy |
32,698
+1,721
| +6% | +$273K | 0.01% | 743 |
|
|
2020
Q4 | $4.69M | Buy |
30,977
+688
| +2% | +$98.3K | 0.01% | 730 |
|
|
2020
Q3 | $4.1M | Buy |
30,289
+450
| +2% | +$61K | 0.01% | 675 |
|
|
2020
Q2 | $4.08M | Sell |
29,839
-602
| -2% | -$76.7K | 0.01% | 651 |
|
|
2020
Q1 | $3.28M | Buy |
30,441
+1,516
| +5% | +$175K | 0.01% | 643 |
|
|
2019
Q4 | $3.49M | Sell |
28,925
-376
| -1% | -$41.9K | 0.01% | 711 |
|
|
2019
Q3 | $2.92M | Buy |
29,301
+78
| +0.3% | +$8.16K | 0.01% | 719 |
|
|
2019
Q2 | $3.19M | Sell |
29,223
-1,019
| -3% | -$108K | 0.01% | 692 |
|
|
2019
Q1 | $3.38M | Buy |
30,242
+492
| +2% | +$54K | 0.01% | 649 |
|
|
2018
Q4 | $2.87M | Buy |
29,750
+1,114
| +4% | +$118K | 0.01% | 634 |
|
|
2018
Q3 | $3.49M | Sell |
28,636
-185
| -0.6% | -$21.8K | 0.01% | 616 |
|
|
2018
Q2 | $3.17M | Sell |
28,821
-37,447
| -57% | -$4M | 0.01% | 624 |
|
|
2018
Q1 | $7.07M | Buy |
66,268
+51,138
| +338% | +$5.67M | 0.01% | 586 |
|
|
2017
Q4 | $1.61M | Buy |
15,130
+4,918
| +48% | +$526K | ﹤0.01% | 737 |
|
|
2017
Q3 | $1.14M | Buy |
10,212
+897
| +10% | +$95.9K | ﹤0.01% | 794 |
|
|
2017
Q2 | $963K | Buy |
9,315
+453
| +5% | +$44.6K | ﹤0.01% | 818 |
|
|
2017
Q1 | $866K | Buy |
8,862
+2,904
| +49% | +$278K | ﹤0.01% | 809 |
|
|
2016
Q4 | $527K | Buy |
5,958
+843
| +16% | +$76.7K | ﹤0.01% | 849 |
|
|
2016
Q3 | $494K | Sell |
5,115
-84
| -2% | -$7.99K | ﹤0.01% | 844 |
|
|
2016
Q2 | $446K | Sell |
5,199
-750
| -13% | -$67.3K | ﹤0.01% | 837 |
|
|
2016
Q1 | $517K | Hold |
5,949
| – | – | ﹤0.01% | 784 |
|
|
2015
Q4 | $671K | Sell |
5,949
-30
| -0.5% | -$3.26K | ﹤0.01% | 755 |
|
|
2015
Q3 | $605K | Buy |
5,979
+300
| +5% | +$36K | ﹤0.01% | 757 |
|
|
2015
Q2 | $698K | Buy |
5,679
+2,085
| +58% | +$250K | ﹤0.01% | 695 |
|
|
2015
Q1 | $411K | Buy |
3,594
+876
| +32% | +$96.6K | ﹤0.01% | 826 |
|
|
2014
Q4 | $275K | Sell |
2,718
-405
| -13% | -$39.4K | ﹤0.01% | 850 |
|
|
2014
Q3 | $285K | Sell |
3,123
-237
| -7% | -$20.8K | ﹤0.01% | 831 |
|
|
2014
Q2 | $288K | Buy |
3,360
+555
| +20% | +$43.7K | ﹤0.01% | 838 |
|
|
2014
Q1 | $221K | Buy |
+2,805
| New | +$234K | ﹤0.01% | 851 |
|
Other funds holding IBB
CB
Eaton Vance Management's IBB Position: Q3 2022 in Review
Eaton Vance Management reduced its iShares Biotechnology ETF (IBB) stake by 1% in Q3 2022, selling an estimated $48.3K and leaving 37,142 shares worth $4.34M. The position accounts for 0.01% of the portfolio, ranked #825.
Eaton Vance Management first reported a position in IBB in Q1 2014 and has held it in 35 quarters since. The position peaked at $7.07M in Q1 2018. 829 funds tracked by Wall St. Rank hold IBB as of Q3 2022.
- Eaton Vance Management held 37,142 shares of iShares Biotechnology ETF worth $4.34M as of Q3 2022.
- Eaton Vance Management sold 389 iShares Biotechnology ETF shares in Q3 2022, an estimated $48.3K.
- iShares Biotechnology ETF made up 0.01% of Eaton Vance Management's portfolio in Q3 2022, its #825 holding.
- Eaton Vance Management first reported a position in iShares Biotechnology ETF in Q1 2014 and has held it in 35 quarters since.
- Eaton Vance Management's iShares Biotechnology ETF position peaked at $7.07M in Q1 2018.
- 829 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.